New Mexico Educational Retirement Board decreased its position in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 8.3% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 20,900 shares of the biopharmaceutical company’s stock after selling 1,900 shares during the period. New Mexico Educational Retirement Board’s holdings in Alexion Pharmaceuticals were worth $2,870,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of the company. Morgan Stanley increased its stake in Alexion Pharmaceuticals by 112.0% in the first quarter. Morgan Stanley now owns 585,482 shares of the biopharmaceutical company’s stock worth $70,983,000 after buying an additional 309,299 shares during the period. DekaBank Deutsche Girozentrale increased its stake in Alexion Pharmaceuticals by 18.2% in the first quarter. DekaBank Deutsche Girozentrale now owns 114,493 shares of the biopharmaceutical company’s stock worth $14,017,000 after buying an additional 17,642 shares during the period. Sumitomo Mitsui Asset Management Company LTD increased its stake in Alexion Pharmaceuticals by 10.9% in the first quarter. Sumitomo Mitsui Asset Management Company LTD now owns 18,859 shares of the biopharmaceutical company’s stock worth $2,286,000 after buying an additional 1,849 shares during the period. Baird Financial Group Inc. increased its stake in Alexion Pharmaceuticals by 219.0% in the first quarter. Baird Financial Group Inc. now owns 14,606 shares of the biopharmaceutical company’s stock worth $1,771,000 after buying an additional 10,028 shares during the period. Finally, LS Investment Advisors LLC increased its stake in Alexion Pharmaceuticals by 13.0% in the first quarter. LS Investment Advisors LLC now owns 6,131 shares of the biopharmaceutical company’s stock worth $743,000 after buying an additional 706 shares during the period. 95.14% of the stock is owned by institutional investors and hedge funds.

Shares of Alexion Pharmaceuticals, Inc. (NASDAQ ALXN) opened at 136.85 on Thursday. The firm has a market cap of $30.54 billion, a PE ratio of 59.35 and a beta of 1.41. Alexion Pharmaceuticals, Inc. has a 52 week low of $96.18 and a 52 week high of $145.42. The firm has a 50-day moving average of $128.92 and a 200-day moving average of $122.85.

Alexion Pharmaceuticals (NASDAQ:ALXN) last posted its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $1.56 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.08 by $0.48. The firm had revenue of $912 million for the quarter, compared to the consensus estimate of $846.15 million. Alexion Pharmaceuticals had a net margin of 15.31% and a return on equity of 12.47%. The business’s revenue for the quarter was up 21.1% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.13 EPS. On average, analysts expect that Alexion Pharmaceuticals, Inc. will post $5.60 EPS for the current year.

COPYRIGHT VIOLATION NOTICE: This news story was first published by Daily Political and is the sole property of of Daily Political. If you are viewing this news story on another publication, it was copied illegally and reposted in violation of U.S. & international copyright legislation. The original version of this news story can be viewed at https://www.dailypolitical.com/2017/08/10/new-mexico-educational-retirement-board-sells-1900-shares-of-alexion-pharmaceuticals-inc-nasdaqalxn.html.

ALXN has been the subject of several recent analyst reports. BMO Capital Markets reaffirmed an “outperform” rating and issued a $158.00 target price on shares of Alexion Pharmaceuticals in a research note on Wednesday, May 24th. Zacks Investment Research raised shares of Alexion Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, April 18th. Raymond James Financial, Inc. reaffirmed a “strong-buy” rating and issued a $176.00 target price on shares of Alexion Pharmaceuticals in a research note on Tuesday, May 9th. Goldman Sachs Group, Inc. (The) reaffirmed a “buy” rating and issued a $142.00 target price on shares of Alexion Pharmaceuticals in a research note on Friday, June 9th. Finally, Leerink Swann reaffirmed a “buy” rating on shares of Alexion Pharmaceuticals in a research note on Tuesday, May 23rd. Five analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and three have assigned a strong buy rating to the stock. Alexion Pharmaceuticals presently has an average rating of “Buy” and an average target price of $156.89.

In other news, Director Bros. Advisors Lp Baker acquired 1,348,955 shares of the business’s stock in a transaction on Wednesday, June 14th. The shares were purchased at an average cost of $116.32 per share, with a total value of $156,910,445.60. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Ann M. Veneman sold 700 shares of Alexion Pharmaceuticals stock in a transaction on Monday, July 31st. The stock was sold at an average price of $137.74, for a total transaction of $96,418.00. Following the transaction, the director now directly owns 6,315 shares in the company, valued at $869,828.10. The disclosure for this sale can be found here. Insiders have acquired a total of 2,019,734 shares of company stock worth $235,606,846 over the last ninety days. Insiders own 4.35% of the company’s stock.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.